Department of Orthopaedic Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, No 321 Zhongshan Road, Nanjing 210008, People's Republic of China.
Mol Cell Biochem. 2010 Aug;341(1-2):225-33. doi: 10.1007/s11010-010-0453-2. Epub 2010 Apr 8.
The overexpression of the type 1 insulin-like growth factor receptor (IGF-1R) has been reported to be associated with malignant transformation, tumor development and chemo- or radioresistance of tumor cells. Previously, we have reported that inhibition of IGF-1R could reverse the radioresistance of human osteosarcoma cells. However, whether inhibition of IGF-1R could enhance chemosensitivity of ostesosarcoma cells is unclear. In this study, lentivirus-mediated shRNA was employed to downregulate endogenous IGF-1R expression to study the function of IGF-1R in chemoresistance of osteosarcoma cells. Results showed that lentivirus-mediated shRNA targeting IGF-1R combined with chemotherapy (CDDP or DTX) could lead to growth suppression of osteosarcoma cells not only in vitro but also in vivo. Moreover, inhibition of IGF-1R gene combined with chemotherapy also synergistically enhanced Caspase-3-mediated apoptosis of osteosarcoma cells. The synergistical enhancement of apoptosis might be associated with downregulation of Bcl-2 and upregulation of Bax in osteosarcoma cells induced by IGF-1R inhibition. Therefore, the overexpression of IGF-1R gene might play important roles in chemoresistance of osteosarcoma cells, and lentivirus-mediated RNAi targeting IGF-1R would be an attractive anti-cancer strategy to chemosensitization of osteosarcoma cell.
IGF-1R 的过度表达与恶性转化、肿瘤发生以及肿瘤细胞的化疗和放疗耐药性有关。此前,我们已经报道 IGF-1R 的抑制可以逆转人骨肉瘤细胞的放射抵抗性。然而,抑制 IGF-1R 是否可以增强骨肉瘤细胞的化疗敏感性尚不清楚。在这项研究中,我们使用慢病毒介导的 shRNA 下调内源性 IGF-1R 表达,以研究 IGF-1R 在骨肉瘤细胞化疗耐药性中的作用。结果表明,针对 IGF-1R 的慢病毒介导的 shRNA 与化疗(CDDP 或 DTX)联合使用不仅可以在体外,而且可以在体内抑制骨肉瘤细胞的生长。此外,IGF-1R 基因的抑制与化疗联合使用还协同增强了 Caspase-3 介导的骨肉瘤细胞凋亡。这种协同增强的凋亡可能与 IGF-1R 抑制诱导的骨肉瘤细胞中 Bcl-2 的下调和 Bax 的上调有关。因此,IGF-1R 基因的过表达可能在骨肉瘤细胞的化疗耐药性中起重要作用,慢病毒介导的靶向 IGF-1R 的 RNAi 可能是一种有吸引力的骨肉瘤细胞化疗增敏的抗癌策略。